J&J Innovative Medicine Europe, Middle East & Africa (EMEA) in the news

Janssen Sciences Ireland UC develops innovative medicines for complex diseases, operates major manufacturing sites in Cork, and calls for improved healthcare funding and infrastructure in Ireland to enhance patient access and support value-based care.

Europe's focus on healthcare cost-cutting, driven by budget constraints and aging populations, negatively impacts patients, health systems, and economies by neglecting the long-term value of innovation.

Europe can enhance patient outcomes by better leveraging real-world data through federated networks and policy initiatives to improve healthcare decision-making and access to innovative treatments.

Johnson & Johnson successfully completed one-year Phase 3 trials for its oral psoriasis pill icotrokinra, showing lasting skin clearance in adults and adolescents.

The European Commission approved guselkumab for treating moderate to severe plaque psoriasis in children aged 6+, the first IL-23 inhibitor approved for pediatric use, based on positive Phase 3 trial results.

Johnson & Johnson Innovative Medicine develops innovative treatments across multiple therapeutic areas to improve patient and health system outcomes globally.

Laetitia Decroix Guilloux has been named President of Johnson & Johnson Innovative Medicine in Canada to lead the division's strategic growth and pharmaceutical innovation.

Pricing strategies are based on local health value and collaboration with governments to ensure patients can afford and access innovative treatments.

About 10% of people worldwide have immune-mediated diseases, but few receive effective advanced treatments.

J&J Innovative Medicine forms strategic partnerships to develop innovative therapies for challenging diseases like cancer, autoimmune disorders, and neurological conditions.

The European Commission authorized J&J's Tremfya for treating moderate to severe ulcerative colitis, based on clinical trial success and established safety.

Martin Price of J&J EMEA discusses enhancing access to innovative cancer treatments and building public trust in the oncology sector.

EMA's CHMP recommended approval of a faster, safer subcutaneous Rybrevant-Leclaza combo for treating EGFR-mutant NSCLC in Europe.

Johnson & Johnson's short film uses a maze metaphor to highlight the challenges of severe depression and the vital role of caregivers, aiming to raise awareness and support for patients.

Johnson & Johnson is expanding the U.S. rollout of the TECNIS Odyssey intraocular lens, offering cataract patients improved continuous vision at all distances with fewer visual disturbances.

The European Commission approved Johnson & Johnson's single-pill combination therapy Yuvanci for treating pulmonary arterial hypertension, improving patient adherence and outcomes.

Johnson & Johnson Innovative Medicine supports annual disclosure of financial transfers to healthcare professionals to promote transparency and improve patient outcomes.

Strategic commitment to leveraging data science, AI, and the European Health Data Space to improve patient outcomes and healthcare innovation.

J&J, BioMarin, and Telix announce key leadership changes to strengthen talent, R&D, and business development amid strategic growth.

Europe's mental health crisis demands innovative, personalized treatments, with Johnson & Johnson leading efforts to tailor therapies using precision medicine and technology.